611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
New, Natural Pesticides Effective Against Mosquitoes: StudyDoctors Not Talking About Newer Meningitis VaccineAHA: 'Bad' Cholesterol Can Be Deadly in Otherwise Healthy PeopleHealth Tip: Keep Your Bladder Healthier4 Ways to Protect Your Child From Allergic Reactions at SchoolFDA Approves 1st Generic EpiPenThinning Retina Seen as Early Warning Sign for Parkinson'sSleep in Your Contacts, Risk Serious Eye Damage: CDCAHA: Wildfire Smoke Threatens Health of Those Near and FarStem Cells Restore Some Vision in Blind MiceHealth Tip: Are You at Risk for Macular Degeneration?Dialysis Linked to Dementia in SeniorsGene Test Predicts Risk of 5 Common DiseasesStudy Hints at Why Women Suffer More Migraines Than MenHealth Tip: Making an Emergency CallHealth Tip: Identify Bug BitesHealth Tip: Most Americans are OverweightA Weak Grip May Signal Future Health Trouble -- Even in KidsEye Disease Link to Alzheimer's SeenNew Research Suggests Glaucoma May Be an Autoimmune DiseaseHealth Tip: Fight Frequent FatigueEarly Onset Type 1 Diabetes Linked to Heart Disease, Shorter LifeAHA: Obesity May Increase Risk for Peripheral Artery DiseaseHealth Tip: Getting a Second Opinion Before SurgeryHealth Tip: Avoid Mosquito BitesPreschoolers' Parents May Be Unprepared to Treat AsthmaSchool Prep Includes Planning Allergy, Asthma ManagementHave Glaucoma and Need to Switch Eye Docs? Here's What You Need to DoHealth Woes Hit 1 in 7 Babies Exposed to Zika in U.S. TerritoriesStudy Urges Genetic Testing of Relatives of Aortic Disease PatientsHepatitis-Infected Kidneys a Safe Option for Transplant: StudySigns Your Child Might Have Hearing LossHow to Keep Foodborne Illness at BayAHA: Air Pollution Exposure Linked to Enlarged HeartsScientists Trace Link Between Head Injuries and Parkinson'sScans Help Spot Heart Trouble Early in People With LupusHealth Tip: Warmer Weather Triggers RashesToo Many Kidney Disease Patients in the Dark About DietGerms Gaining Resistance to Hand Gels in HospitalsHealth Tip: Recognize Signs of a Urinary Tract InfectionMore Research Links Sunscreens to Marine-life DamageLyme Disease Striking More Americans in More StatesClimate Change Means More Deadly Heat Waves: StudyObesity Warps the Shape, Function of Young HeartsHere's What Happened When 1 Unvaccinated NYC Kid Got MeaslesGyms With Tanning Beds Send Mixed MessageSummers Less Smoggy Now, But Winter Air Hasn't ImprovedIt's Hot Outside: How to Stay Safe When Thermometers Rise3-Pronged Approach to Cancer PreventionCould Psoriasis Patients Eat Their Way to Fewer Symptoms?
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

AAN: Erenumab Shows Promise for Hard-to-Treat Migraine


HealthDay News
Updated: Apr 19th 2018

new article illustration

THURSDAY, April 19, 2018 (HealthDay News) -- For patients with episodic migraine who have failed prior preventive migraine treatments (PMTs), erenumab is associated with an increase in the proportion of patients achieving a ≥50 percent reduction in mean monthly migraine days (MMDs), according to a study presented at the annual meeting of the American Academy of Neurology, held from April 21 to 27 in Los Angeles.

Uwe Reuter, M.D., from The Charité -- University Medicine Berlin, and colleagues conducted a 12-week study in which 246 patients with episodic migraine who had failed two to four prior PMTs were randomly allocated to receive erenumab or placebo. At baseline, 38.6, 37.8, and 22.8 percent of patients had failed two, three, and four prior PMTs, respectively.

The researchers found that the mean MMDs was 9.3 and mean monthly acute migraine-specific medication days (MSMDs) was 4.6. The proportion of patients achieving a ≥50 percent reduction in MMDs was higher in erenumab- versus placebo-treated patients at week 12 (30.3 versus 13.7 percent; odds ratio, 2.73). There were greater reductions in MMDs and MSMDs with erenumab than placebo at week 12 (mean difference in MMDs: −1.61; mean difference in MSMDs: −1.73). Erenumab had a similar safety and tolerability profile to placebo.

"Our results show that people who thought their migraines were difficult to prevent may actually have hope of finding pain relief," Reuter said in a statement.

The study was funded by Novartis, the manufacturer of erenumab.

Press Release
More Information